Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News SQZ Biotechnologies Co SQZB

Healthcare Biotechnology
SQZ Biotechnologies Company is a clinical-stage biotechnology company. The Company is focused on unlocking the full potential of cell therapies to benefit patients. In oncology, it is developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. Its clinical-stage cell therapy candidates include SQZ Enhanced APC (eAPC... see more

Recent & Breaking News (OTCPK:SQZB)

SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates

Business Wire November 8, 2023

SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting

Business Wire November 3, 2023

SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates

Business Wire August 10, 2023

SQZ Biotechnologies Provides Update on Collaboration with Roche

Business Wire July 25, 2023

SQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock Split

Business Wire June 15, 2023

SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates

Business Wire May 10, 2023

SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial

Business Wire March 22, 2023

SQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio Updates

Business Wire March 22, 2023

SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange

Business Wire January 18, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SQZ Biotechnologies Company - SQZ

PR Newswire January 4, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SQZ Biotechnologies Company - SQZ

Newsfile December 30, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SQZ Biotechnologies Company - SQZ

PR Newswire December 26, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SQZ Biotechnologies Company - SQZ

PR Newswire December 19, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SQZ Biotechnologies Company - SQZ

Newsfile December 17, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SQZ Biotechnologies Company - SQZ

PR Newswire December 12, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SQZ Biotechnologies Company - SQZ

Newsfile December 10, 2022

Bronstein, Gewirtz & Grossman, LLC Announces SQZ Biotechnologies Company (SQZ) Investigation

PR Newswire December 7, 2022

SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress

Business Wire December 6, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SQZ Biotechnologies Company - SQZ

PR Newswire December 5, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SQZ Biotechnologies Company - SQZ

Newsfile December 1, 2022